Please check your internet connection and try again.
# Walethmade bromide
## Overview
Walethmade bromide is a synthetic opioid agonist.
## Primary Indications
* Moderate to severe pain.
## Adult Dosing
* **Oral:** 5 mg every 4-6 hours as needed. Maximum dose not established, but titrate to effective pain relief with minimal adverse effects.
* **IM/IV:** 2.5 mg every 3-4 hours as needed. Maximum dose not established.
* Dosing should be individualized based on patient's pain severity, response, and tolerance.
## Pediatric Dosing
* Safety and efficacy in pediatric patients have not been established. Consult specialized pediatric pain management resources for available guidelines.
## Dose Adjustments
* **Renal Impairment:** Use with caution. Dose reduction may be necessary. Specific recommendations vary; consult renal dosing guidelines.
* **Hepatic Impairment:** Use with caution. Dose reduction may be necessary. Consult hepatic dosing guidelines.
* **Elderly:** Consider starting at the lower end of the dosing range due to potential for increased sensitivity and decreased organ function.
## Contraindications
* Known hypersensitivity to walethmade bromide.
* Significant respiratory depression.
* Acute or severe bronchial asthma or hypercapnia.
* Concurrent use with MAO inhibitors or within 14 days of their discontinuation.
## Adverse Effects
* **Common:** Sedation, dizziness, nausea, vomiting, constipation, pruritus, headache, dry mouth.
* **Serious:** Respiratory depression, opioid-induced constipation, hypotension, bradycardia, seizures (rarely), CNS depression, physical dependence, addiction, withdrawal symptoms.
## Key Drug Interactions
* **CNS Depressants (e.g., benzodiazepines, alcohol, sedatives, hypnotics):** Increased risk of profound sedation, respiratory depression, coma, and death.
* **MAO Inhibitors:** Potentially life-threatening interactions, including severe respiratory depression, cardiovascular collapse, and serotonin syndrome.
* **CYP3A4 Inhibitors/Inducers:** May alter walethmade bromide plasma concentrations.
* **Anticholinergics:** Increased risk of urinary retention and severe constipation.
## Monitoring
* Pain assessment (frequency, intensity, location).
* Respiratory rate, depth, and pattern.
* Level of consciousness and sedation.
* Bowel function.
* Blood pressure and heart rate.
* Signs of opioid withdrawal if dose is reduced or discontinued.
## Clinical Pearls
* Titrate dose slowly to achieve adequate analgesia while minimizing side effects.
* Consider bowel regimen proactively for all patients receiving regular doses due to high incidence of constipation.
* Educate patients on the risks of sedation, falls, and potential for misuse.
* When switching from other opioids, consider equianalgesic dosing carefully and monitor closely for withdrawal or over-sedation.
***
*Disclaimer: This information is intended for clinical decision-making and is not a substitute for professional medical advice. Always consult the most current prescribing information, institutional protocols, and relevant literature to ensure safe and effective patient care.*
